related_research

Ataxia Trial of BHV-4157

The purpose of this study is to compare the efficacy of BHV-4157 versus placebo on ataxia symptoms in subjects with spinocerebellar ataxia (SCA).

Summary

  • Study director: Michael Geschwind, MD, PhD
  • Sponsor: Biohaven Pharmaceutical Holding Company Ltd.
  • Recruiting?: Yes
  • Official study title: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia

IDEAS: Imaging Dementia – Evidence for Amyloid Scanning

The IDEAS study will investigate how a specific type of brain scan – known as an amyloid PET scan – helps guide doctors in treating mild cognitive impairment or dementia, and whether these changes in treatment lead to better medical outcomes for patients.

Summary

  • Study director: Gil Rabinovici, MD
  • Sponsor: Alzheimer’s Association
  • Recruiting?: Yes
  • Official study title: IDEAS: Imaging Dementia – Evidence for Amyloid Scanning

Parkinson's Disease Trial of iPad-Based Cognitive Exercise

The primary goal of this study is to carry out a randomized clinical trial assessing the efficacy of two different versions of iPad-based EVO game-play (EVO-multitask and EVO-visual search) on cognition in PD patients

Summary

  • Study director: Joel Kramer, PsyD
  • Recruiting?: Yes
  • Official study title: Cerebrovascular and Parkinson’s Disease EVO Study
  • Fox Trial Finder identifier: 4918

PET Imaging in Aging Population

The aim of this study is to identify the relationship between amyloid aggregation in the brain and brain structure and function. Participants who want to volunteer for research on healthy aging should first join the Healthy Aging Program.

Participants who want to volunteer for research on healthy aging should first join the Healthy Aging Program. Joining this program involves a single visit every 15 months and will enable you to get involved in other related research projects, like this study, if you’re interested.

Summary

Alzheimer's Disease Trial with Crenezumab - Phase 3

The purpose of this study is to evaluate the efficacy and safety of crenezumab in patients with prodromal to mild Alzheimer’s disease.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: F. Hoffmann-La Roche Ltd.
  • Recruiting?: Yes
  • Official study title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease

Progressive Supranuclear Palsy Trial of ABBV-8E12

The purpose of this study is to evaluate the efficacy and safety of ABBV-8E12 in patients with progressive supranuclear palsy.

Summary

  • Study director: Richard Tsai, MD
  • Sponsor: AbbVie
  • Recruiting?: Yes
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
  • ClinicalTrials.gov identifier: NCT02985879

4 Repeat Tauopathy Neuroimaging Initiative – Cycle 2 (4RTNI-2)

This is the second cycle of a study that aims to identify the best methods of analysis for tracking PSP and CBD over time.

Summary

  • Study director: Adam Boxer, MD PhD
  • Sponsor: National Institutes of Health (NIH)
  • Recruiting?: Yes
  • Official study title: 4 Repeat Tauopathy Neuroimaging Initiative – Cycle 2 (4RTNI-2)

HIV Elder Study

The goal of this study is to determine the efficacy of mindfulness based stress reduction (MBSR) to alleviate stress, anxiety and depressive symptoms and improve attention among patients aged 60 or older who suffer from HIV-associated neurocognitive disorders (HAND) and have maximized treatment options.

Summary

Alzheimer’s Disease Trial with Aducanumab

The primary purpose of this study is to find out whether aducanumab has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer’s disease (AD) by comparing it to placebo and to evaluate its safety (side effects), and to find out more about aducanumab.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Biogen
  • Recruiting?: Yes
  • Official study title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Progressive Supranuclear Palsy Trial with C2N-8E12

The primary purpose of this study is to determine the safety, tolerability, and maximally tolerated dosage of C2N-8E12, and anti-tau monoclonal antibody. C2N-8E12 is an immunotherapy (antibody) drug designed to bind to and to remove tau protein. The tau protein is believed to build up to abnormally high levels in the brains of individuals with PSP. This abnormal accumulation is associated with clinical progression of the disease.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: C2N Diagnostics
  • Recruiting?: No
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Supranuclear Palsy
Syndicate content